Why Harpoon Therapeutics Inc. [HARP] Stock Still Has Countless Sunny Days Ahead

Harpoon Therapeutics Inc. [HARP] has traded in a range of $10.27 to $25.02 in the last 1 year. As of this writing, the stock is at $14.03, up 5.17%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, HARP shares are -10.59% down with the monthly amount drift of -19.35% and seems bad in a long time frame.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


On 8, December 2020, Harpoon Therapeutics Reports Clinical Progress Across All Four TriTAC® Pipeline Development Programs. According to news published on Yahoo Finance, HPN424 has shown confirmed partial response in treatment of metastatic castration-resistant prostate cancer in highest fixed dose cohort (160 ng/kg) of continuing Phase 1/2a dose escalation trial.

Analyst Birdseye View:

The most recent analyst activity for Harpoon Therapeutics Inc. [NASDAQ:HARP] stock was on February 28, 2020, when it was Initiated with a Buy rating from SunTrust. Before that, on May 22, 2020, Piper Sandler Recapitulated an Overweight rating and elevated its amount target to $35. On February 03, 2020, H.C. Wainwright Initiated a Buy rating and boosted its price target on this stock to $28. On November 14, 2019, ROTH Capital Initiated a Buy rating and increased its price target to $25. On May 24, 2019, Citigroup Resumed a Buy rating and increased its price target to $23. On April 23, 2019, Robert W. Baird Initiated an Outperform rating. On March 05, 2019, Wedbush Initiated an Outperform rating and boosted its target amount on this stock to $23.

In the past 52 weeks of trading, this stock has oscillated between a low of $10.27 and a peak of $25.02. Right now, according to Wall Street analyst the average 12-month amount target is $31.63. At the most recent market close, shares of Harpoon Therapeutics Inc. [NASDAQ:HARP] were valued at $14.03.


Harpoon Therapeutics Inc. [NASDAQ:HARP] most recently reported quarterly sales of 3.89 billion, which represented growth of 178.60%. This publicly-traded organization’s revenue is $94,705 per employee, while its income is -$911,016 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -39.81, -65.26, -62.84 and -60.39 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 13.69 and the whole liability to whole assets at 8.46. It shows enduring liability to the whole principal at 12.57 and enduring liability to assets at 0.08 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 13.10 points at 1st support level, the second support level is making up to 12.86. But as of 1st resistance point, this stock is sitting at 13.72 and at 14.10 for 2nd resistance point.

Harpoon Therapeutics Inc. [HARP] reported its earnings at -$0.53 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.49/share signifying the difference of -0.04 and -8.20% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.51 calling estimates for -$0.47/share with the difference of -0.04 depicting the surprise of -8.50%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Harpoon Therapeutics Inc. [NASDAQ:HARP] is 3.50. Likewise, the Quick ratio is also the same, showing Cash ratio at 6.58. Now if looking for a valuation of this stock’s amount to sales ratio it’s 55.67 and it’s amount to book ratio is 3.91.

Insider Stories

The most recent insider trade was by Wesche Holger, Chief Scientific Officer, and it was the sale of 10000.0 shares on Oct 01. Erbez Georgia, the Chief Financial Officer, completed a purchase of 5000.0 shares on Aug 19. On Aug 18, Erbez Georgia, Chief Financial Officer, completed a purchase of 2098.0 shares.